Inify Laboratories AB

Share Issue/Capital Change • Nov 12, 2025

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

STOCKHOLM - November 12, 2025 - Inify Laboratories AB ("Inify" or the "Company")

will in a separate press release call for an extraordinary general meeting (the

"EGM") to be held on December 4, 2025 at 10:00 CET to resolve on afully

guaranteed share issue of a total of 28,571,429 new shares generating gross

proceeds of approximately NOK 100 million.

The board of directors' reasons for proposing the equity issue are to ensure

financial stability and persistence. This is due to a slight delay in the fit

-out project and larger-than-expected investments related to the establishment

in the UK. This, in combination with insight of lengthy processes to convene

business with the public healthcare sector has led the board of directors to

decide to finance the expansion through equity.

The proposed issue of shares will be divided into two tranches with (i) a fully

guaranteed private placement of approximately NOK 92 million with a minimum

subscription per subscriber of the NOK equivalent of EUR 100,000 directed pro

-rata towards existing shareholders holding more than 1,000,000 shares in the

Company (the "Private Placement"), and (ii) a fully guaranteed repair issue of

approximately NOK 8 million (the "Repair Issue"), directed pro-rata towards

existing shareholders that did not participate in the Private Placement and who

hold less than 1,000,000 shares in the Company. For technical reasons, the

shares in the Private Placement and the Repair Issue will be issued at nominal

value to SB1 Markets AS ("SB1 Markets") to be allocated to shareholders who have

applied for shares in the share issues, at the subscription price. The

subscription price per share in the Private Placement and the Repair Issue will

be NOK 3.50 per share.

The basis for the subscription price is the market value of the share together

with what the board of directors considers to be a market conformant discount,

corresponding to what would be applied to the subscription price in a rights

issue. The reason for not applying the shareholders' pre-emption rights is to

reduce the costs for the Company which would otherwise be associated with a

rights issue. As only shareholders in the Company will be able to participate,

on a pro-rata basis, in the Private Placement and the Repair Issue, as

applicable. Shareholders are, however, expected to be able to maintain their pro

-rata shareholding in the Company after the Private Placement and the Repair

Issue, as long as such shareholders submit an application corresponding to their

pro-rata shareholding in the Company.

MonsunAS and Auris AS(the "Guarantors"), companies controlled by the same owners

as the two largest shareholdersGallivantS.àr.l. and Tauri AS, respectively, have

entered into guarantee undertakings covering in total 100% of the Private

Placement and the Repair Issue (the "Guarantee Commitment"). The Guarantors will

not receive any compensation for the Guarantee Commitment.

Application period for Private Placement

The application period for the Private Placement is proposed to commence on 9

December 2025, and to end on 16 December 2025 at 16:30 hours CET (the "Private

Placement Application Period"). The board of directors will have the right to

extend or shorten the Private Placement Application Period at any time and for

any reason on short, or without, notice. If the Private Placement Application

Period is extended or shortened, the other dates referred to herein might be

changed accordingly.

Record date and application period for the Repair Issue

The Repair Issue is proposed, subject to applicable securities law, to be

directed towards all existing shareholders in the Company, other than the

shareholders eligible to take part in the Private Placement, as of 16 December

2025 (as registered in Euronext Securities Oslo (the "VPS") or Euroclear, as

applicable, on 18 December 2025 (the "RecordDate")), who are not resident in a

jurisdiction where such offering would be unlawful or would (in jurisdictions

other than Norway) require any prospectus, filing, registration or similar

action.

Provided that the EGM resolves to carry out the Repair Issue, the Company will,

if required, publish a national (Norwegian) prospectus in the beginning of

January 2026 and thereafter commence the two-week application period for the

Repair Issue (the "Repair Issue Application Period"). Shareholders with shares

registered with the VPS as of the Record Date is intended to receive non

-transferable subscription rights, which they will then receive at the start of

the Repair Issue Application Period. Shareholders with shares registered

directly with Euroclear as of the Record Date will not receive any subscription

rights. Instead, such shareholders will receive an application form which shall

be used to apply for subscription for shares in the Repair Issue.

The key dates for the Repair Issue are set out below:

· Last day of trading in the Company's shares including the right to

participate in Repair Issue: 16 December 2025

· Ex-date: 17 December 2025

· Record date: 18 December 2025

· Repair Issue Application Period: on or around 12 January 2026 - 26 January

Settlement

The date for payment of the Private Placement and the Repair Issue is expected

to be on or about 16 February 2026 (the "Payment Date"). The new shares in the

Private Placement and the Repair Issue are expected to be delivered on or about

19 February 2026, subject to turnaround time for registration of the share

capital increasesrelating to the Private Placement and the Repair Issue with the

Swedish Companies Registration Office ("SCRO"). The shares allocated in the

Private Placement and the Repair Issue will be tradable on Euronext Growth Oslo

when the new shares have been registered with the SCRO and registered by

Euroclear Sweden and VPS, respectively, expected on or about 19 February 2026.

Commencement of the Private Placement and the Repair Offering is subject to

approval by the EGM.

For further information, please contact CEO, Fredrik Palm,

fredrik.palm@inify.com,or visit

https://www.inify.com (https://protect.checkpoint.com/v2/r02/___https://www.inify

.com___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3OjFjM

TM6YjE3M2Q4MTI2YmQxZjEyYzJmYWVhMzdlYWFiMTNiZGVlMjdkZjA1MjdlMTNjN2JlOTMyYmNkZDZmNz

ViNjhhMjpwOlQ6VA)

Advisors

SB1 Markets has been appointed as financial advisor in connection with the

Private Placement and the Repair Issue. Schjødt law firm acts as legal counsel

to the Company.

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in

histopathology, with a focus on streamlining patient pathways. The company

performs clinical diagnostics in prostate cancer and gastroenterology, providing

an integrated service that spans from early sample handling to final diagnosis.

The laboratory system is scalable both in handling large volumes of patient

samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to

tissue preparation and diagnosis - using a fully digital, standardised and AI

-assisted workflow. The diagnosis is always performed by a pathologist and is

assisted by Inify's proprietary AI, proven to have world-leading precision in

clinical evaluations. The entire workflow is supported by a tailor-made system

that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden,

with local laboratories in Sweden and the UK. The company's share is listed on

Euronext Growth Oslo(https://live.euronext.com/en/product/equities/SE0017486103

-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwti

zhydjvznynjxdXJ556a9b*~*658

-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc3

NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZlO

TE5NmJhMjpwOlQ6VA)) under the ticker

INIFY.(https://live.euronext.com/en/product/equities/SE0017486103

-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwti

zhydjvznynjxdXJ556a9b*~*658

-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc3

NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZlO

TE5NmJhMjpwOlQ6VA))

This information is considered to be inside information pursuant to the EU

Market Abuse Regulation (MAR) and is subject to the disclosure requirements

pursuant to MAR article 17 and section 5-12 the Norwegian Securities Trading

Act.

This stock exchange announcement was published by Ann-Charlotte Linderoth, Inify

Laboratories AB on the time and date provided.

Important information

The release, announcement or distribution of this press release may, in certain

jurisdictions, be subject to restrictions. The recipients of this press release

in jurisdictions where this press release has been published or distributed

shall inform themselves of and follow such restrictions. The recipient of this

press release is responsible for using this press release, and the information

contained herein, in accordance with applicable rules in each jurisdiction. The

information in this press release does not contain or constitute an offer to

acquire, subscribe or otherwise trade in shares, subscription rights or other

securities in the Company in any jurisdiction. Any invitation to the persons

concerned to subscribe for shares in the Repair Issue will only be made through

the national (Norwegian) prospectus which the Company expects to publish in the

beginning of January 2026.

This press release does not identify or suggest, or purport to identify or

suggest, the risks (direct or indirect) that may be associated with an

investment in new shares. Any investment decision in connection with the Private

Placement and Repair Issue must be made on the basis of all publicly available

information relating to the Company and the Company's shares. Such information

has not been independently verified by SB1 Markets. The information contained in

this announcement is for background purposes only and does not purport to be

full or complete. No reliance may be placed for any purpose on the information

contained in this announcement or its accuracy or completeness. SB1 Markets is

acting for the Company in connection with the transaction and no one else and

will not be responsible to anyone other than the Company for providing the

protections afforded to its clients nor for giving advice in relation to the

transaction or any other matter referred to herein.

This press release does not constitute a recommendation concerning any

investor's option with respect to the Private Placement and Repair Issue. Each

investor or prospective investor should conduct his, her or its own

investigation, analysis and evaluation of the business and data described in

this announcement and publicly available information. The price and value of

securities can go down as well as up. Past performance is not a guide to future

performance.

The information contained in this press release is not intended for, and must

not be accessed by, or distributed or disseminated, directly or indirectly, in

whole or in part, to persons resident or physically present in the United States

of America (including its territories and possessions, any state of the United

States and the District of Columbia) (the "United States"), Australia, Canada,

Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any

other jurisdiction where such action is wholly or partially subject to legal

restrictions, or would require additional prospectuses, registration or other

measures than those required by Swedish law. The information in the press

release does not constitute any offer regarding subscription rights, paid

subscribed shares or shares in the Company ("Securities") to any person in said

jurisdictions. The information in the press release may not be forwarded or

reproduced in such a manner that contravenes such restrictions or gives cause to

such requirements.

No securities have been or will be registered under the United States Securities

Act of 1933, as amended (the "Securities Act") or the securities legislation of

any state or other jurisdiction in the United States and may not be offered,

subscribed for, exercised, used, pledged, sold, resold, granted, delivered or

otherwise transferred, directly or indirectly, in or into the United States

except pursuant to an applicable exemption from, or in a transaction not subject

to, the registration requirements under the Securities Act and in compliance

with the securities legislation in the relevant state or any other jurisdiction

of the United States.

Within the European Economic Area ("EEA"), no public offering of Securities is

made in other countries than Sweden or Norway. In other member states of the EU,

such an offering of Securities may only be made in accordance with the

Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other

member states of the EEA which have implemented the Prospectus Regulation in its

national legislation, any offer of Securities may only be made in accordance

with an applicable exemption in the Prospectus Regulation and/or in accordance

with an applicable exemption under a relevant national implementation measure.

In the United Kingdom, this document and any other materials in relation to the

securities described herein is only being distributed to, and is only directed

at, and any investment or investment activity to which this document relates is

available only to, and will be engaged in only with, "qualified investors" who

are (i) persons having professional experience in matters relating to

investments who fall within the definition of "investment professionals" in

Article 19(5) of the Financial Services and Markets Act 2000 (Financial

Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling

within Article 49(2)(a) to (d) of the Order (all such persons together being

referred to as "relevant persons"). In the United Kingdom, any investment or

investment activity to which this communication relates is available only to,

and will be engaged in only with, relevant persons. Persons who are not relevant

persons should not take any action on the basis of this press release and should

not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the

Company's intentions, beliefs, or current expectations about and targets for the

Company's future results of operations, financial condition, liquidity,

performance, prospects, anticipated growth, strategies and opportunities and the

markets in which the Company's operates. Forward-looking statements are

statements that are not historical facts and may be identified by words such as

"believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will",

"should", "could", "aim" or "might", or, in each case, their negative, or

similar expressions. The forward-looking statements in this press release are

based upon various assumptions, many of which are based, in turn, upon further

assumptions. Although the Company believes that the expectations reflected in

these forward-looking statements are reasonable, it can give no assurances that

they will materialize or prove to be correct. Because these statements are based

on assumptions or estimates and are subject to risks and uncertainties, the

actual results or outcome could differ materially from those set out in the

forward-looking statements as a result of many factors. Such risks,

uncertainties, contingencies and other important factors could cause actual

events to differ materially from the expectations expressed or implied in this

release by such forward-looking statements. The Company does not guarantee that

the assumptions underlying the forward-looking statements in this press release

are free from errors and readers of this press release should not place undue

reliance on the forward-looking statements in this press release. The

information, opinions and forward-looking statements that are expressly or

implicitly contained herein speak only as of its date and are subject to change

without notice. Neither the Company nor anyone else undertake to review, update,

confirm or to release publicly any revisions to any forward-looking statements

to reflect events that occur or circumstances that arise in relation to the

content of this press release.

FDI

The Company assesses that it conducts a business of strategic interest under the

Act (2023:560) on the Review of Foreign Direct Investments (the "FDI Act"). In

accordance with the FDI Act, the Company must inform potential investors that

its operations may fall within the scope of the regulation and that the

investment may be subject to a notification requirement. If an investment is

subject to notification, it must be reported to the Inspectorate of Strategic

Products (ISP) before being completed. An investment may be subject to

notification if the investor, any entity within its ownership structure, or any

party on whose behalf the investor is acting, following the completion of the

investment, holds voting rights corresponding to or exceeding any of the

thresholds of 10, 20, 30, 50, 65, or 90 percent of the total number of votes in

the Company. The investor may be subject to an administrative sanction fee if a

notifiable investment is carried out before ISP has either: i) decided to take

no action on the notification, or ii) approved the investment. Each shareholder

should consult an independent legal advisor regarding the potential

applicability of the FDI Act in relation to the Rights Issue for the individual

shareholder.

Information to distributors

Solely for the purposes of the product governance requirements contained within:

(a) EU Directive 2014/65/EU on markets in financial instruments, as amended

("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU)

2017/593 supplementing MiFID II; and (c) local implementing measures (together,

the "MiFID II Product Governance Requirements"), and disclaiming all and any

liability, whether arising in tort, contract or otherwise, which any

"manufacturer" (for the purposes of the MiFID II Product Governance

Requirements) may otherwise have with respect thereto, the shares in the Company

have been subject to a product approval process, which has determined that such

shares are: (i) compatible with an end target market of retail investors and

investors who meet the criteria of professional clients and eligible

counterparties, each as defined in MiFID II; and (ii) eligible for distribution

through all distribution channels as are permitted by MiFID II (the "Target

Market Assessment"). Notwithstanding the Target Market Assessment, Distributors

should note that: the price of the shares in the Company may decline and

investors could lose all or part of their investment; the shares in the Company

offer no guaranteed income and no capital protection; and an investment in the

shares in the Company is compatible only with investors who do not need a

guaranteed income or capital protection, who (either alone or in conjunction

with an appropriate financial or other adviser) are capable of evaluating the

merits and risks of such an investment and who have sufficient resources to be

able to bear any losses that may result therefrom. The Target Market Assessment

is without prejudice to the requirements of any contractual, legal or regulatory

selling restrictions in relation to the new share issue. Furthermore, it is

noted that, notwithstanding the Target Market Assessment, SB1 Markets will only

procure investors who meet the criteria of professional clients and eligible

counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute:

(a) an assessment of suitability or appropriateness for the purposes of MiFID

II; or (b) a recommendation to any investor or group of investors to invest in,

or purchase, or take any other action whatsoever with respect to the shares in

the Company.

Each distributor is responsible for undertaking its own target market assessment

in respect of the shares in the Company and determining appropriate distribution

channels.